J Bohlius

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi [A pioneer turns homeward: Society of Development and Continuing Education developer Thilo Kober goes back down under]
    Julia Bohlius
    Cochrane Haematological Malignancies Group, ,
    Z Arztl Fortbild Qualitatssich 100:402. 2006
  2. ncbi Erythropoietin or darbepoetin for patients with cancer
    J Bohlius
    University Hopsital, Cologne University, Department I for Internal Medicine, Cologne, Germany, D 50924
    Cochrane Database Syst Rev 3:CD003407. 2006
  3. ncbi Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    J Natl Cancer Inst 98:708-14. 2006
  4. ncbi Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma
    Frauke Naumann
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 98:E2. 2006
  5. ncbi High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis
    Alexander Greb
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Cancer Treat Rev 33:338-46. 2007
  6. ncbi Fourth biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 98:E1. 2006
  7. ncbi Cancer-related anemia and recombinant human erythropoietin--an updated overview
    Julia Bohlius
    Cochrane Haematological Malignancies Group, University of Cologne, Cologne, Germany
    Nat Clin Pract Oncol 3:152-64. 2006
  8. ncbi Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 111:25-41. 2008
  9. ncbi Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    J Natl Cancer Inst 97:489-98. 2005
  10. ncbi Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 26:132-49. 2008

Detail Information

Publications15

  1. ncbi [A pioneer turns homeward: Society of Development and Continuing Education developer Thilo Kober goes back down under]
    Julia Bohlius
    Cochrane Haematological Malignancies Group, ,
    Z Arztl Fortbild Qualitatssich 100:402. 2006
  2. ncbi Erythropoietin or darbepoetin for patients with cancer
    J Bohlius
    University Hopsital, Cologne University, Department I for Internal Medicine, Cologne, Germany, D 50924
    Cochrane Database Syst Rev 3:CD003407. 2006
    ..Therapeutic alternatives are recombinant human erythropoietin (Epo), darbepoetin (Darbepo) and red blood cell transfusions...
  3. ncbi Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    J Natl Cancer Inst 98:708-14. 2006
    ..08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events...
  4. ncbi Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma
    Frauke Naumann
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 98:E2. 2006
  5. ncbi High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis
    Alexander Greb
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Cancer Treat Rev 33:338-46. 2007
    ..Randomized controlled trials (RCTs) reported conflicting results on the impact of high-dose chemotherapy (HDCT) and autologous stem cell transplantation in the first-line treatment of patients with aggressive non-Hodgkin lymphoma (NHL)...
  6. ncbi Fourth biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 98:E1. 2006
  7. ncbi Cancer-related anemia and recombinant human erythropoietin--an updated overview
    Julia Bohlius
    Cochrane Haematological Malignancies Group, University of Cologne, Cologne, Germany
    Nat Clin Pract Oncol 3:152-64. 2006
    ..Treatment of patients beyond the correction of anemia, however, has to be regarded as experimental and is potentially harmful, so should only be conducted in clinical trials...
  8. ncbi Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 111:25-41. 2008
    ..The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents...
  9. ncbi Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    J Natl Cancer Inst 97:489-98. 2005
    ....
  10. ncbi Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 26:132-49. 2008
    ..The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents...
  11. ncbi Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    Br J Haematol 122:413-23. 2003
    ..However, there is no evidence that G-CSF/GM-CSF improved CR and OS in this clinical setting...
  12. ncbi Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis
    Michael Steurer
    Innsbruck Medical University, Division of Hematology and Oncology, Anichstrasse 35, A 6020 Innsbruck, Austria
    Cancer Treat Rev 32:377-89. 2006
    ..However, none was able to show a survival advantage. Thus, a systematic Cochrane review may be able to further define the role of purine analogues in the first-line treatment of B-CLL...
  13. ncbi Third biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 97:E2. 2005
  14. ncbi Second biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 97:E1. 2005
  15. ncbi The erythropoietin receptor in normal and cancer tissues
    Wolfgang Jelkmann
    Institute of Physiology, University of Luebeck, Ratzeburger Allee 160, D 23538 Luebeck, Germany
    Crit Rev Oncol Hematol 67:39-61. 2008
    ....